Celularity Inc. (CELU) is a clinical-stage regenerative and cellular medicine company, not an ETF. Because it has only a single recent, attributable analyst price target — WBB Securities (analyst Steve Brozak) set a $6 target when it upgraded the stock from Hold to Buy on September 9, 2025 — there is no meaningful multi-analyst average to calculate. Earlier targets from HC Wainwright, Morgan Stanley, Oppenheimer, Truist, and Alliance Global Partners date to 2021–2023 and are clearly stale. For context only, the lone current figure is $6; it is far above the market price and should not be read as a realistic near-term objective.
Given the lack of a credible analyst consensus, the $1.50 level used here comes from public discussion and a verifiable structural milestone: the initial conversion price of the notes issued in Celularity's September 2026 recapitalization. The notes carry a 10% interest rate, a 24-month maturity, and an initial conversion price of $1.50 per share. That level is frequently cited in market commentary as a reference point for the shares, and it sits comfortably more than 10% above the current price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of mid-November 2026, Celularity shares traded near $0.46, within a 52-week range of roughly $0.42 to $2.55. Reaching $1.50 would require a move of about 225%, which is a very large percentage gain. The path is complicated by a sharp recent decline: the stock has fallen from around $1.26 in late October 2026, reflecting heavy volatility and thin liquidity typical of a penny stock.
Fundamentally, the company reported fiscal 2025 revenue of about $26.6 million, down roughly 51% from $54.2 million in 2024, alongside a net loss near $92 million. Cash on hand was reported around $0.6 million with total debt near $36 million, and management has acknowledged going-concern and financing risk. Reaching $1.50 would therefore likely require both a stabilization of operations toward the company's stated goal of positive operating cash flow by early 2027 and sustained investor confidence in its restructuring.
Several verified developments could support a recovery. In October 2026 the company regained compliance with Nasdaq's periodic reporting requirements after filing overdue quarterly reports. A recapitalization completed a first closing in September 2026, raising over $10 million with up to $25 million contemplated, and management said monthly cash burn had fallen by more than $1 million. In August 2026 Celularity announced a manufacturing collaboration to produce Dezawa MuseCell, with the partner projecting more than $300 million in aggregate purchases over five years. It also out-licensed its biomaterials business for up to $30 million and eliminated roughly $13 million of liabilities. These steps address liquidity and reporting risks that have weighed on the stock. From what I see, these operational updates are worth monitoring closely.
The obstacles are substantial. The company has posted declining revenue, persistent losses, negative operating cash flow, and a going-concern disclosure. Its cash balance is very small relative to its debt, and future capital raises or note conversions could dilute existing shareholders. Later closings of the recapitalization are not assured, and the stock's thin liquidity and wide bid-ask spreads amplify downside risk. The fact that the shares trade well below the $1.50 conversion price itself signals market skepticism about the recapitalization's terms.
The shares sit near the lower end of their 52-week range, with the $0.42 area representing a recent low and potential support level. On the upside, the round-number $1.00 level and, notably, the $1.50 note-conversion price act as resistance references, while the 52-week high near $2.55 marks a more distant ceiling. The stock's multi-month downtrend and heavy recent selling suggest that any move toward $1.50 would first require reclaiming and holding above short-term resistance zones in the $0.60–$0.80 range.
Analyst price targets typically reflect a research horizon of roughly 12 months, but the lone WBB Securities figure is more than a year old and should be treated cautiously. Key items to watch include the filing of the quarter ended September 30, 2026, further closings of the recapitalization, progress toward the company's positive-operating-cash-flow goal for the first quarter of 2027, the manufacturing collaboration's execution, and any additional financing or note conversions. Earnings, cash-burn updates, and analyst coverage changes will be the most direct signals. I'm watching this closely as the next earnings update approaches.
Whether Celularity (CELU) can reach $1.50 depends on a turnaround that has yet to be demonstrated. The target is a structural reference — the initial note conversion price — rather than a consensus of analysts, and the roughly 225% move required is very large. Support comes from the completed recapitalization, restored Nasdaq compliance, and new commercial arrangements, while going-concern risk, negative cash flow, and potential dilution remain the principal obstacles. Investors should weigh the thin, stale analyst coverage, the stock's sharp recent decline, and upcoming financial filings rather than treating $1.50 as a probable destination.
For traders seeking an additional lens on names like Celularity, AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I have found this approach helpful in my own review of volatile micro-cap names, providing a data-driven complement to fundamental research without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CELU saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
CELU moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CELU crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CELU entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in 213 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.197) is normal, around the industry mean (3.596). P/E Ratio (-0.228) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.244) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CELU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology